CN107787330B - 用于治疗杜氏肌营养不良的抗flt-1抗体 - Google Patents

用于治疗杜氏肌营养不良的抗flt-1抗体 Download PDF

Info

Publication number
CN107787330B
CN107787330B CN201680032814.0A CN201680032814A CN107787330B CN 107787330 B CN107787330 B CN 107787330B CN 201680032814 A CN201680032814 A CN 201680032814A CN 107787330 B CN107787330 B CN 107787330B
Authority
CN
China
Prior art keywords
ser
seq
antibody
val
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680032814.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN107787330A (zh
Inventor
D·基夫
H·德哈德
N·德乔格
S·加布里埃尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Shire Human Genetics Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd, Shire Human Genetics Therapies Inc filed Critical Takeda Pharmaceutical Co Ltd
Priority to CN202210037246.0A priority Critical patent/CN114539408B/zh
Priority to CN202510178279.0A priority patent/CN120290577A/zh
Publication of CN107787330A publication Critical patent/CN107787330A/zh
Application granted granted Critical
Publication of CN107787330B publication Critical patent/CN107787330B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680032814.0A 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体 Active CN107787330B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210037246.0A CN114539408B (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体
CN202510178279.0A CN120290577A (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562144251P 2015-04-07 2015-04-07
US62/144,251 2015-04-07
US201662307645P 2016-03-14 2016-03-14
US62/307,645 2016-03-14
PCT/US2016/026352 WO2016164528A1 (en) 2015-04-07 2016-04-07 Anti-flt-1 antibodies for treating duchenne muscular dystrophy

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202510178279.0A Division CN120290577A (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体
CN202210037246.0A Division CN114539408B (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体

Publications (2)

Publication Number Publication Date
CN107787330A CN107787330A (zh) 2018-03-09
CN107787330B true CN107787330B (zh) 2022-02-01

Family

ID=55754471

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201680032814.0A Active CN107787330B (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体
CN202510178279.0A Pending CN120290577A (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体
CN202210037246.0A Active CN114539408B (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202510178279.0A Pending CN120290577A (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体
CN202210037246.0A Active CN114539408B (zh) 2015-04-07 2016-04-07 用于治疗杜氏肌营养不良的抗flt-1抗体

Country Status (10)

Country Link
US (3) US10787515B2 (enExample)
EP (2) EP4056593A1 (enExample)
JP (3) JP6993880B2 (enExample)
CN (3) CN107787330B (enExample)
AU (2) AU2016246722B2 (enExample)
ES (1) ES2910783T3 (enExample)
MA (1) MA41899A (enExample)
MX (1) MX2017012828A (enExample)
PL (1) PL3280734T3 (enExample)
WO (1) WO2016164528A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41899A (fr) 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
US20230287122A1 (en) * 2018-11-29 2023-09-14 Harbour Biomed Therapeutics Limited Anti-pd-l1 antibody preparation
MY208487A (en) * 2019-08-02 2025-05-13 Cttq Akeso Shanghai Biomed Tech Co Ltd Anti-pd-1 antibody and medical use thereof
CN114230666B (zh) * 2021-12-20 2022-09-02 南京诺唯赞生物科技股份有限公司 一种t7 rna聚合酶的单克隆抗体及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
EP2377555A3 (en) 2004-11-18 2011-11-23 Imclone LLC Antibodies against vascular endothelial growth factor receptor-1
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JP6169495B2 (ja) * 2011-02-07 2017-07-26 アガミン・エルエルシー 妊娠関連高血圧性障害を治療または予防するための方法およびシステム
EA037501B1 (ru) * 2013-01-28 2021-04-05 Шир Хьюман Дженетик Терапис, Инк. Способ лечения мышечной дистрофии дюшенна путем введения анти-flt-1-антитела
TW201517916A (zh) * 2013-03-15 2015-05-16 Lilly Co Eli Ｖｅｇｆｒ１抗體之治療用途
MA41899A (fr) 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne

Also Published As

Publication number Publication date
MA41899A (fr) 2018-02-13
EP3280734B1 (en) 2022-01-26
JP7456989B2 (ja) 2024-03-27
CN114539408B (zh) 2025-03-11
AU2016246722A1 (en) 2017-10-26
PL3280734T3 (pl) 2022-07-04
CA2981954A1 (en) 2016-10-13
US12435146B2 (en) 2025-10-07
AU2022200466B2 (en) 2024-06-13
JP2018518153A (ja) 2018-07-12
JP7741225B2 (ja) 2025-09-17
AU2016246722B2 (en) 2021-10-28
WO2016164528A9 (en) 2017-01-12
EP3280734A1 (en) 2018-02-14
US20210206860A1 (en) 2021-07-08
WO2016164528A1 (en) 2016-10-13
BR112017021414A2 (pt) 2018-07-03
CN114539408A (zh) 2022-05-27
CN107787330A (zh) 2018-03-09
JP6993880B2 (ja) 2022-01-14
EP4056593A1 (en) 2022-09-14
HK1249912A1 (en) 2018-11-16
MX2017012828A (es) 2018-06-19
JP2024069463A (ja) 2024-05-21
ES2910783T3 (es) 2022-05-13
JP2022040124A (ja) 2022-03-10
AU2022200466A1 (en) 2022-02-17
US20240076387A1 (en) 2024-03-07
US20180072806A1 (en) 2018-03-15
US10787515B2 (en) 2020-09-29
CN120290577A (zh) 2025-07-11

Similar Documents

Publication Publication Date Title
US12435146B2 (en) Anti-Flt-1 antibodies for treating Duchenne muscular dystrophy
JP7051150B2 (ja) 気分障害の治療及び診断のための抗－配列類似性１９を持つファミリー、メンバーａ５抗体の用途
BR122012004341A2 (pt) Anticorpos monoclonais contra proteína rgm a e usos destes
US20210163603A1 (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
CA2981954C (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
HK40079861A (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
HK1249912B (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
BR112017021414B1 (pt) Anticorpos anti-flt-1 e composição farmacêutica compreendendo os referidos anticorpos
BR122024023570A2 (pt) Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno
HK1217710B (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210719

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: SHIRE HUMAN GENETIC THERAPIES, Inc.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant